Toll Free Helpline (India): 1800 1234 070

Rest of World: +91-9810852116

NAAS RATING: 5.23, Impact Factor: RJIF 5.98 | Free Publication Certificate
updates
NAAS Rating: 5.23 new
Vol. 7, Issue 1 (2018)

Some values of endothelial dysfunction, functional state of the liver, carbohydrate metabolism and lipid blood spectrum in patients with a combined course of non-alcoholic steatohepatitis and chronic obstructive pulmonary disease depending on the g894t gene polymorphism of the endothelial no-synthase

Author(s):
Tetyana Tsintar, Oleksandr Fediv and Hanna Stupnytska
Abstract:
The purpose of the study was to analyze the incidence of alleles / genotypes of the G894T polymorphic variant of the eNOS gene in patients with non-alcoholic steatohepatitis (NASH) combined with chronic obstructive pulmonary disease (COPD) and their association with the functional state of the liver, endothelial dysfunction, carbohydrate metabolism and lipid blood spectrum. The polymorphism of the G894T gene of the eNOS was studied using a polymerase chain reaction in 40 patients with NASH in combination with COPD. It has been established that there is a more pronounced manifestation of endothelial dysfunction with the comorbidity of NASH and COPD and the presence of the T allele (as evidenced by higher endothelin-1 levels (by 30.5%) and sVCAM-1 (by 24.4%) with the simultaneous low level nitrates / nitrites in the blood) and more significant disorders in the blood lipid spectrum (especially regarding the level of low density lipoproteins and atherogenicity index) and the functional state of the liver with more pronounced cholestatic syndrome, cytolysis and decreased protein-synthetic liver function.
Pages: 289-294  |  635 Views  7 Downloads
How to cite this article:
Tetyana Tsintar, Oleksandr Fediv, Hanna Stupnytska. Some values of endothelial dysfunction, functional state of the liver, carbohydrate metabolism and lipid blood spectrum in patients with a combined course of non-alcoholic steatohepatitis and chronic obstructive pulmonary disease depending on the g894t gene polymorphism of the endothelial no-synthase. Pharma Innovation 2018;7(1):289-294.
The Pharma Innovation Journal